Four late-stage programs approaching simultaneous approval decisions; encaleret's May 2027 PDUFA with clean Phase 3 data is the first test of whether BridgeBio can convert its pipeline into a multi-franchise rare-disease company

BridgeBio is a late-stage rare-disease company with four programs approaching regulatory decisions, including one approved treatment for a heart condition and three not yet approved candidates for calcium regulation, bone growth, and muscle weakness.

BridgeBio enters 2027 with BEYONTTRA (acoramidis) already approved for ATTR-CM, encaleret at a May 2027 PDUFA after a clean Phase 3, and infigratinib under FDA review for achondroplasia. The thesis resolves on whether encaleret wins approval and infigratinib captures share against Ascendis Pharma's TransCon CNP in a crowded achondroplasia market. BBP-418 in LGMD2I/R9 adds a third NDA-stage asset, but a $720 million cash position covering only to late 2027 leaves little buffer if any launch stumbles.